CD8A and neoplasm: In addition to the direct pharmacological damage of tumor cells, on the other hand, the combined application of LPS-RGD-Nb36-DOX and activated CD8+ T cells activated the antitumor activity for these effector cells, further enhancing the cellular immunity attack on tumor cells.